Resverlogix Granted Approval of Two China Patents for Cardiovascular Drug

Resverlogix Corp. of Canada announced that its lead molecule, RVX-208, a first-in-class, small molecule treatment for cardiovascular disease, was granted two China patent approvals. With the new IP protection, which extends to 2029, Resverlogix will seek to out-license China rights for the clinical stage drug candidate. According to Resverlogix, RVX-208, a BET bromodomain inhibitor, works by transporting plaque from the blood stream to the liver, where it is eliminated from the body. Resverlogix has completed two Phase IIb trials of RVX-208. More details.... Stock Symbol: (TSX: RVX) Share this with colleagues: // //